Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | MGMT | P16455 | 3/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 2/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684049 | 0.85 | GDA (0.58) | GDAPDPK1MGMTDPP4PI4KA | |
| SCHEMBL29509029 | 0.85 | GDA (0.58) | GDAPDPK1MGMTDPP4PI4KA | |
| SCHEMBL27461919 | 0.85 | GDA (0.58) | GDAPDPK1MGMTDPP4PI4KA | |
| Acetic Acid SCHEMBL1903435 | 0.84 | GDA (0.50) | GDAPDPK1MGMTDPP4PI4KA | |
| SCHEMBL30107648 | 0.83 | GDA (0.56) | GDAPDPK1MGMTDPP4PI4KA | |
| SCHEMBL31435111 | 0.83 | GDA (0.51) | GDAPDPK1MGMTDPP4PI4KA | |
| Zinc Ion SCHEMBL31405446 | 0.82 | GDA (0.54) | GDAPDPK1MGMTDPP4PI4KA | |
| SCHEMBL6045492 | 0.81 | GDA (0.53) | GDAPDPK1MGMTDPP4PI4KA | |
| SCHEMBL9393667 | 0.80 | PDPK1 (0.49) | GDAPDPK1MGMTDPP4PI4KA | |
| SCHEMBL8506351 | 0.80 | PDPK1 (0.51) | GDAPDPK1MGMTDPP4PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119375400-A | Sample pretreatment method for detecting CD38 enzyme activity in whole blood sample and method for detecting blood CD38 enzyme activity by high performance liquid chromatography | 北京医院 | 2025-01-28 | — | — | CN | claimed |
| CN-116519923-A | Detection method of inducer in induced rat hyperuricemia kidney injury model | 四川大学华西医院 | 2023-08-01 | — | — | CN | claimed |
| CN-107541103-A | A kind of indoor anti-radiation building coating and preparation method thereof | 佛山市三水区嫚娅环保科技有限公司 | 2018-01-05 | — | — | CN | claimed |
| CN-105906629-A | Technological process for synthesizing adenine | 宿迁远扬生物科技有限公司 | 2016-08-31 | — | — | CN | claimed |
| EP-2157182-A2 | Modified short interfering RNA | Qiagen GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| CN-119264184-B | Preparation method of dideoxy ring-opened ribonucleotide triphosphate and intermediate | 天津奥利芙生物技术有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119375400-A | Sample pretreatment method for detecting CD38 enzyme activity in whole blood sample and method for detecting blood CD38 enzyme activity by high performance liquid chromatography | 北京医院 | 2025-01-28 | — | — | CN | disclosed |
| CN-119264184-A | Preparation method of dideoxy ring-opened ribonucleotide triphosphate and intermediate | 天津奥利芙生物技术有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-117069723-A | Refining method of pharmaceutical grade adenine | 江西阿尔法高科药业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116519923-A | Detection method of inducer in induced rat hyperuricemia kidney injury model | 四川大学华西医院 | 2023-08-01 | — | — | CN | disclosed |
| CN-116334028-A | Nucleoside hydrolase mutant, engineering bacterium and application | 浙江工业大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-112143662-B | Recombinant pichia pastoris engineering bacteria and application thereof in preparation of purine | 浙江工业大学 | 2023-01-06 | — | — | CN | disclosed |
| US-8859749-B2 | Modified short interfering RNA | QIAGEN GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2157182-A2 | Modified short interfering RNA | Qiagen GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090197332-A1 | Modified Short Interfering RNA | QIAGEN GMBH (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1863912-A2 | MODIFIED SHORT INTERFERING RNA | Qiagen GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102970-A2 | MODIFIED SHORT INTERFERING RNA | QIAGEN GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197332-A1 | Modified Short Interfering RNA | NSUN2, NSUN3, METTL16 | GDA 1238/4885PDPK1 4708/4885MGMT 1172/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | GDA 716/4885PDPK1 3656/4885MGMT 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.